MiniMed Go / InPen smart MDI system
MiniMed
What it is
A commercially launched smart-injection system combining the reusable InPen, MiniMed Go app, and either Abbott's Instinct CGM (up to 15-day wear) or Medtronic's standalone Simplera. It automatically logs half-unit injections, tracks active insulin, warns about missed doses, and calculates meal and correction doses; it is injection support, not automated insulin delivery. An open Class II recall requires app versions 1.0/1.1 to update to 1.2 or later because some nighttime missed-dose and high-glucose alerts may not fire.
Editorial review: .
Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Dose guidance: Uses current glucose and active insulin for meal and correction calculations, missed-dose reminders, and prompts when more insulin may be needed. Settings still have to be established correctly with a clinician.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 90 × 18 + 88 × 20 + 92 × 15 + 90 × 12 + 72 × 15 + 50 × 10 + 65 × 10 = 8070; divide by total weight 100. Unrounded weighted result: 80.7.
InPen sends dose amount and timing to the app automatically by Bluetooth, with NFC recovery available; doses taken with another device still need manual entry.[1]
Uses current glucose and active insulin for meal and correction calculations, missed-dose reminders, and prompts when more insulin may be needed. Settings still have to be established correctly with a clinician.[1]
Real-time Instinct or Simplera glucose, insulin-on-board, dose calculations, alerts, and injection history live in one app rather than in parallel logs.[1]
InPen delivers in half-unit increments, a meaningful advantage for smaller doses and younger users.[1]
One app handles onboarding, dose advice, reports, and both pen and CGM data. The pen battery lasts one year without recharging, but the pen then needs replacement; an open Class II recall requires app versions 1.0/1.1 to update because some enabled alerts may fail at night.[5]
Supports Humalog, NovoLog, and Fiasp cartridges plus Instinct or Simplera, but no third-party CGM and no open data-control pathway; this remains a closed MiniMed ecosystem.[1]
The US launch occurred during the week of 25 May 2026, and MiniMed's US product page lists pharmacy access and major commercial-plan coverage; a selected-market EMEA rollout began earlier in 2026. Coverage and age indication vary with the chosen sensor.[4]
These tools do not automate basal insulin. Scores reflect what the shipping product does for injection users: reliably capturing doses, turning glucose and insulin-on-board data into useful guidance, and reducing daily burden without hiding regional or insulin-cartridge lock-in.
The full picture
MiniMed Go is the clearest current answer to the question, "what does modern diabetes technology look like if I do not want a pump?" It combines the reusable InPen smart insulin pen, a compatible continuous glucose monitor, and the MiniMed Go phone app. The pen sends each injection to the app automatically; the app combines that history with current glucose and active insulin, then calculates meal and correction doses and can prompt for a missed dose.1
The hardware delivers half-unit doses and uses Humalog, NovoLog, or Fiasp U-100 cartridges. Its sealed battery is designed to last one year, after which the pen is replaced. The CGM choice is MiniMed-only: Abbott's Instinct sensor or Medtronic's standalone Simplera. A Dexcom or retail Libre cannot be substituted.1
This is not a closed loop. The app recommends an amount; the person still dials and injects it. Correct settings, current meal/glucose information, connectivity, and manual logging of any dose taken outside InPen all matter. MiniMed explicitly warns that bad settings or missing data can produce a wrong recommendation.1
Open Class II app recall. FDA recall Z-2778-2026 covers MiniMed Go app versions 1.0.0 and 1.1.0 on iOS and Android. When “Set day and night” is off, enabled Missed Dose or Correct High Glucose alerts may not fire during the night, which can leave a missed rapid-acting dose unnoticed and delay treatment. MiniMed instructed users to update to version 1.2.0 or later. This is an app software correction affecting 3,465 installations worldwide, not a recall of the reusable InPen itself.5
The availability date had drifted on this site. MiniMed Go was FDA-cleared with Instinct in January 2026, began a selected-market EMEA rollout with Simplera in February, and launched in the United States during the week of 25 May 2026.234 MiniMed's current US product page says it is available through pharmacies and covered by major commercial health plans.1
Age depends on the sensor: with Instinct, the app is indicated from age 7 and can be used at ages 2–6 with adult caregiver supervision; Simplera is 18+; InPen alone is intended for all ages with supervision under 7.1
September access check. MiniMed’s 1 September 2026 update confirms European commercial launch of the 780G with Instinct and MiniMed Go with Instinct Go. Product configurations and eligibility remain region-specific.6
Sources
- [1]MiniMed Go system product page and specifications · Manufacturer — Confirms current US pharmacy availability, InPen half-unit dosing and one-year battery, Instinct/Simplera integration, active-insulin dose calculations, compatible U-100 insulins, and sensor-specific age labels.
MiniMed. MiniMed Go system — product page, specifications and safety information.
- [2]MiniMed announces FDA clearance for MiniMed Go with Abbott's Instinct sensor · Manufacturer · 2026-01-12
MiniMed. FDA clearance for MiniMed Go Smart MDI with the Instinct sensor (12 January 2026).
- [3]MiniMed begins EMEA commercial launch of MiniMed Go with Simplera · Manufacturer · 2026-02-25
MiniMed. EMEA commercial launch of MiniMed Go with Simplera (25 February 2026).
- [4]MiniMed confirms US launch of MiniMed Go · Manufacturer · 2026-05-27 — The release says the launch occurred during the week of 25 May 2026.
MiniMed. MiniMed to showcase MiniMed Flex and MiniMed Go at ADA (27 May 2026; states "following this week's launch").
- [5]FDA Class II recall Z-2778-2026 — MiniMed Go app versions 1.0 and 1.1 · Regulatory decision · 2026-07-23 — Open recall for 3,465 iOS and Android app installations worldwide. If day and night scheduling is off, enabled missed-dose or correct-high-glucose alerts may not trigger at night. MiniMed instructed users to update to app version 1.2.0 or later. The recall is the app, not the InPen hardware.
U.S. FDA. Class II Device Recall MiniMed Go App — Z-2778-2026 (initiated 16 June; posted 23 July; open and classified when updated 28 July 2026).
- [6]MiniMed September 2026 pipeline and launch update · Manufacturer · 2026-09-01
MiniMed. September 2026 pipeline and commercial update.